USPTO Patent Grants - Biotech (C12N)

Oligonucleotides for Inducing Paternal UBE3A Expression - Angelman Syndrome Treatment

USPTO granted patent US12596118B2 to Hoffmann-La Roche Inc. covering oligonucleotides capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele for treatment of Angelman syndrome. The 30 claims target the suppressor of the UBE3A paternal allele via hybridization to SNHG14 long non-coding RNA downstream of SNORD109B.